Michael Lederman is an Infectious Disease physician affiliated with University Hospitals of Cleveland. OpenAlex indexes 515 publications with 34,098 citations (h-index 92); ClinicalTrials.gov lists 13 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Infectious Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-8500Registry record last updated 29 Jun 2011.
Clinical trials
- HIV Reservoir Reduction With Interleukin-2
Sponsor: Case Western Reserve University
- AIDS 347: IL-6 Blockade in Treated HIV Infection
Sponsor: Case Western Reserve University
- Study on Interleukin-7 (CYT107) in HIV Patients
Sponsor: Cytheris SA
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202211 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
76%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor33.3%Descovy63%Triumeq37%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor26.7%Tivicay84%Juluca16%Part D<11 patients+ 2 more classes in this area
Cardiovascular
24%Statin8.1%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor6.6%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
19 NIH research awards on record, funded 1987–2020 per NIH RePORTER. The latest:
- Regulatory T cell dysfunction in HIV-1/HCV drug users
Case Western Reserve University
FY2019$199,650R01DA044135
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Anthony Furlan
University Hospitals of Cleveland
Joseph Sabik, MD
University Hospitals of Cleveland
Hans Luders
University Hospitals of Cleveland
Ian Neeland, MD
University Hospitals of Cleveland
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”